Johnson & Johnson’s Revenue by Region (2016-2022)

This statistic highlights Johnson & Johnson’s Revenue by Region, split between Asia-Pacific, Africa, Europe and the United States.

Johnson & Johnson and its subsidiaries are engaged in the research, development, manufacture, and sale of a wide range of healthcare products. Johnson & Johnson is a holding corporation operating in nearly every country in the world. Products connected to human health and well-being are the company’s main emphasis. Consumer health, pharmaceuticals, and medical devices are the three main segments of the company.

Johnson & Johnson’s Revenue by Region

(All figures in billions, except percentages)

In the fiscal year 2020, Johnson and Johnson’s approximately 48% sales occurred outside the U.S. with 23% in Europe, 7% in the Western Hemisphere excluding the United States, and 18% in Asia-Pacific and Africa.

Johnson and Johnson’s total revenue increased from $20.75 billion in Q4 2019 to $22.47 billion in Q4 2020, marking an increase of 8.29% on a year-on-year basis.

Asia-Pacific and Africa

Asia-Pacific and Africa region includes East Asia, North Asia, South Asia, Southeast Asia, Australasia, Melanesia, Micronesia, Polynesia, and Africa.

Johnson and Johnson’s revenue from Asia-Pacific and Africa increased from $3.82 billion in Q4 2019 to $3.99 billion in Q4 2020, an increase of 4.45% on a year-on-year basis. In Q4 2020, Asia-Pacific and Africa contributed 17.76% to the company’s total revenue.

Europe

In Central and Eastern Europe, Johnson & Johnson and its subsidiaries operate in 13 countries ranging from the Baltics to the Balkans.
These nations include Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Serbia, Slovakia and Slovenia and Bosnia and Herzegovina, as well as Romania.

In Q4 2020, Johnson and Johnson’s revenue from the Europe region amounted to $5.27 billion. This was a 7.2% increase compared to $4.66 billion earned in Q4 2019. This region contributed to 23.45% of Johnson and Johnson’s total revenue in Q4 2020.

United States

Johnson and Johnson’s revenue from the United States rose from $10.77 billion in  Q4 2019 to $11.81 billion in Q4 2020, marking an increase of 9.66% on a year-on-year basis. In 2020, the United States contributed 52.56% to the company’s total revenue.

Western Hemisphere, excluding the U.S.

The Western Hemisphere includes North and South America and some parts of Africa, Europe, Antarctica, and Asia.

Johnson and Johnson’s revenue from the Western Hemisphere, excluding the U.S., declined from $1.50 billion in Q4 2019 to $1.40 billion in Q4 2020, a decrease of 6.67% on a year-on-year basis. In Q4 2020, this region contributed 6.63% to the company’s total revenue. The reason for this revenue decline was a 10.2% drop in the company’s sales compared to the previous year.

Company Overview

Johnson and Johnson is an American multinational company founded in 1987. It is headquartered in New Brunswick, New Jersey. There are around 250 subsidiary companies in the corporation, with activities in 60 countries and products sold in over 175 countries. In the calendar year 2020, the corporation made $82.6 billion in global sales. The company has acquired 44 companies and invested over $86 billion in 15 others.

Johnson & Johnson faces tough competition from Bristol Myers Squibb, Merck, Unilever, Pfizer, and Procter & Gamble. The company had employed around 134000 people in 2020. It is traded on the New York Stock Exchange (NYSE) under the ticker symbol “JNJ”.

Did you like Johnson & Johnson’s Revenue by Region statistic?

Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.

You can also get started for free.